Literature DB >> 25984140

Renal tubular dysgenesis and reversible hypocalvaria after intrauterine exposure to an angiotensin receptor blocker.

Akio Yamada1, Yoshikazu Tsuji2, Yuich Kato3, Norishi Ueda4.   

Abstract

Entities:  

Year:  2011        PMID: 25984140      PMCID: PMC4421588          DOI: 10.1093/ndtplus/sfq209

Source DB:  PubMed          Journal:  NDT Plus        ISSN: 1753-0784


× No keyword cloud information.
Sir, We report an infant with renal tubular dysgenesis (RTD) and hypocalvaria after intrauterine exposure to an angiotensin receptor blocker (ARB), in whom RTD is irreversible but hypocalvaria reversible. A female infant was delivered at a gestational age of 35 weeks and 4 days, weighing 1,878 grams, to a gravid 4, para 4, 37-year-old woman, who received an ARB because of hypertension. The mother received olmesartan medoxomil (40 mg/day) during pregnancy. Ultrasound examination revealed oligohydramnios and intrauterine growth restriction. The infant developed anuria and respiratory distress, requiring mechanical ventilation. Serum creatinine was 3.36 mg/dL on Day 4. Serum concentrations of olmesartan medoxomil on Days 1 and 3 were 21.8 ng/mL and 14.7 ng/mL, respectively. Peritoneal dialysis (PD) was started. The mechanical ventilation was stopped at 1 month. The infant was transferred to our hospital. Physical examination revealed a widened anterior fontanel and defects of temporal, occipital and parietal bones but no deformity of limbs. Serum creatinine was 1.98 mg/dL. Ultrasound examination revealed large kidneys with high echogenicity. The cranial computed tomography (CT) revealed hypoplasia of temporal, occipital and parietal bones (Figure 1A). At 2 months, some potion of urine passed and gradually increased to 80–160 mL/day. A renal biopsy was performed, revealing poor differentiation between proximal and distal convoluted tubules and increased intertubular mesenchyme (Figure 1B), indicative of RTD. Most tubules were small and collapsed. Some dilated tubules and tubular necrosis as well as dilated Bowman's capsules, lacking the glomerular tuft, were noted. At 5 months, she was discharged with dialysis. In a recent follow-up at 6 months, serum creatinine was 2.95 mg/dL. The cranial CT showed normal cranial bones. Her growth remains poor, at a weight 2,625 grams, but cognitive development is increasingly progressing.
Fig. 1.

(A): The cranial computed tomography (CT) at 1 month of age reveals calvarial hypoplasia, including hypoplasia of temporal bones. (B): A renal biopsy at 3 months of age reveals poor differentiation between proximal and distal convoluted tubules and increased intertubular mesenchyme. Most tubules were small, collapsed, and surrounded by connective tissue. Some dilated tubules and tubular necrosis are noted. There are some dilated Bowman>'s capsules, lacking the glomerular tuft (magnification ×100, Periodic Acid-Schiff staining).

(A): The cranial computed tomography (CT) at 1 month of age reveals calvarial hypoplasia, including hypoplasia of temporal bones. (B): A renal biopsy at 3 months of age reveals poor differentiation between proximal and distal convoluted tubules and increased intertubular mesenchyme. Most tubules were small, collapsed, and surrounded by connective tissue. Some dilated tubules and tubular necrosis are noted. There are some dilated Bowman>'s capsules, lacking the glomerular tuft (magnification ×100, Periodic Acid-Schiff staining). Table 1 summarizes the clinical characteristics of the reported infants with hypocalvaria and/or RTD after intrauterine exposure to agents that inhibit the renin–angiotensin system (RAS). Three infants after exposure to angiotensin-converting enzyme inhibitors [1] and four infants after exposure to ARBs [2-4], includiing our patient (Case 7), were reported. Of four infants after exposure to ARBs, one developed hypocalvaria alone [3]. All infants with hypocalvaria and acute renal failure, except one case [4], died or remained dependent on PD, suggesting a poor prognosis of these infants. Our patient showed growth of the calvarial bones as described [1, 4], but remained dependent on PD because of RTD with dilated Bowman's capsules lacking the glomerular tuft. This glomerular change, characteristic of severe RTD, was found in three infants with poor outcome [1]. Our observation, together with previous cases, suggests that kidney damage, depending on the severity of RAS inhibition-induced hypotension and/or hypoxia during fetal life, is irreversible and a determinant of outcome, whereas hypocalvaria is reversible.
Table 1.

Review of infants with hypocalvaria and/or RTD after intrauterine exposure to the agents that inhibit RASa

CaseClinical featureInhibitors of RASRenal histopathologyOutcomeReferences
1ARF, IGR, deformities of hand and foot, oligohydramnios, PH, RD, small calvarial bonesCaptoprilb RTD, dilated Bowman’s capsulesDied after birth[1]
2ARF, RD, small calvarial platesLisinoprilb RTD, dilated Bowman’s capsulesSurvived with PD[1]
3ARF, IGR, large fontanels, oligohydramnios, PH, RD, short arms and legs, widened suturesEnalaprilb RTD, dilated Bowman’s capsulesDied after birth[1]
4Deformities of limbs and face, HC, oligohydramnios, PHLosartanc NAFetal death[2]
5HC, oligohydramniosLosartanc NASurvived with normal renal function[3]
6ARF, HC, limb deformities, oligohydramnios, RDValsartanc NASurvived with normal renal function[4]
7ARF, HC, oligohydramnios, RD (present case)Olmesartan medoxomilc RTD, dilated Bowman’s capsules, lacking glomerular tuftSurvived with PD

ARF, acute renal failure; HC, hypocalvaria; IGR, intrauterine growth restriction; NA, not available; PD, peritoneal dialysis; PH, pulmonary hypoplasia; RAS, renin-angiotensin system; RD, respiratory distress; RDT, renal tubular dysgenesis.

Angiotensin-converting enzyme inhibitors.

Angiotensin II type-I receptor blocker.

Review of infants with hypocalvaria and/or RTD after intrauterine exposure to the agents that inhibit RASa ARF, acute renal failure; HC, hypocalvaria; IGR, intrauterine growth restriction; NA, not available; PD, peritoneal dialysis; PH, pulmonary hypoplasia; RAS, renin-angiotensin system; RD, respiratory distress; RDT, renal tubular dysgenesis. Angiotensin-converting enzyme inhibitors. Angiotensin II type-I receptor blocker.
  4 in total

1.  Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists.

Authors:  Maria Vendemmia; Patricia Garcia-Méric; Alina Rizzotti; Farid Boubred; Valérie Lacroze; Agnès Liprandi; Umberto Simeoni
Journal:  J Matern Fetal Neonatal Med       Date:  2005-08

2.  Losartan and fetal toxic effects.

Authors:  H Saji; M Yamanaka; A Hagiwara; R Ijiri
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

3.  Losartan induced fetal toxicity.

Authors:  Bonilla Nayar; Ashwani Singhal; Rajiv Aggarwal; Neena Malhotra
Journal:  Indian J Pediatr       Date:  2003-11       Impact factor: 1.967

4.  Angiotensin-converting enzyme inhibitor fetopathy.

Authors:  P G Pryde; A B Sedman; C E Nugent; M Barr
Journal:  J Am Soc Nephrol       Date:  1993-03       Impact factor: 10.121

  4 in total
  1 in total

1.  Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.

Authors:  Marine Lallemant; Sarah Prévost; François Nobili; Didier Riethmuller; Rajeev Ramanah; Marie-France Seronde; Nicolas Mottet
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Oct-Dec       Impact factor: 1.636

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.